Clinical Trial

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2020-09-18; most recent amendment 2026-03-31.
Trial Details
NCT Number NCT04562129
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Clinigen, Inc.
Conditions Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
Enrollment 29 participants
Start Date 2020-09-24
Primary Completion 2026-07 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-04-01